Detection Of Egfr-Activating Mutations From Plasma Dna As A Potent Predictor Of Survival Outcomes In Fastact 2: A Randomized Phase Iii Study On Intercalated Combination Of Erlotinib (E) And Chemotherapy (C).
JOURNAL OF CLINICAL ONCOLOGY（2013）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要